Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSH1 siRNA is a small interfering RNA designed to silence the expression of Slingshot Homolog 1 (SSH1), a member of the Slingshot family of protein phosphatases. SSH1 plays a pivotal role in regulating the actin cytoskeleton by dephosphorylating and activating cofilin, an actin-binding protein that promotes filament severing and depolymerization. This SSH1-cofilin axis is essential for various cellular processes, including cell migration, cytokinesis, and neuronal development. In the context of oncology, SSH1 is often overexpressed in aggressive tumors, where it facilitates cell invasion and metastasis, making it a target for potential antineoplastic therapies. Furthermore, SSH1 has been implicated in neurodegenerative conditions such as Alzheimer's disease, where its activity contributes to the formation of cofilin-actin rods and tau-mediated synaptic dysfunction. While SSH1 siRNA is a widely utilized research tool for investigating these biological pathways in vitro and in vivo, it has not yet advanced into formal clinical trials as a therapeutic product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SSH1 siRNA.